PHARMACOLOGICAL NEPHROPROTECTION IN CHRONIC KIDNEY DISEASE: CURRENT OPPORTUNITIES AND PERSPECTIVES (REVIEW OF FOREIGN LITERATURE)


Cite item

Full Text

Abstract

A brief literature review analyses pharmacoprotective strategy in most widespread forms of chronic kidney disease: metabolic syndrome, hypertensive angionephrosclerosis, diabetic and non-diabetic nephropathy. Nephroprotective properties of the blockers of rennin-angiotensin-aldosteron system and other antiadrenergic drugs, diuretics, hypolipidemic, antianemic and hypouricemic drugs, active metabolites of vitamin D, metphormine and glytasones are reviewed. The highest efficacy of combined pharmaconephroprotection is demonstrated.

About the authors

A Yu Nikolaev

Russian Medical Academy of Advanced Medical Education

Email: nephrology@mail.ru
Chair of Nephrology and Hemodialysis Moscow

References

  1. Despres J. Potential contribution of metformin to the management of cardiovascular disease risk on patients with metabolic syndrome and type 2 diabetes. Diabet. Metab. 2003; 29: 653—661.
  2. Bakris G.L. Rosiglitazone reduces microalbuminuria and hypertension independently of glycemia in type 2 dibetes. J. Hypertens. 2006; 24: 2047—2055.
  3. Henry R. R., Lincoff A. M. Effect of the dual PPAR-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes. Lancet 2009; 374: 126—135.
  4. Dagenais G. R., Gerstein H. C., Holman R. Effect of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance: results of DREAM trial. Diabet. Care 2008; 31: 1007—1014.
  5. Makino H., Hakeda M., Babazono T. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: the INNOVATION study. J Hypertens. Res. 2008; 31: 657—664.
  6. Ruggenenti P., Perna A. REIN-2 study group. Blood pressure control for renoprotection in patients with non-diabetic CKD. Lancet 2005; 365: 939—946.
  7. Vogt L., de Zeeuw D., Woittiez A. J. Selective COX-2 inhibition reduces proteinuria in renal patients. Nephrol. Dial. Transplant. 2009; 24: 1182—1189.
  8. Marre M., Fernandez M., Garsia-Puig J. Value of natrilix SR in hypertensive type 2 diabetic patients with microalbuminuria. J. Hypertens. Res. 2002; 20 (Suppl. 4): 338—342.
  9. Mogensen C. E., Viberti G. C., Halimi S. Effect of low dose perindopril / indapamide on albuminuria in diabetes. Hypertension 2003; 41: 1063—1071.
  10. ADVANCE collaborate group. Effect of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus. Lancet 2007; 10: 140—167.
  11. Ruggenenti P. Bergamo Nephrologic Diabetic Complication study of the combination trandolapril with verapamil. N. Engl. J. Med. 2004; 351: 1941—1951.
  12. Alleman Y., Fraile B., Lambert M. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: Ex-FAST study. J. Clin. Hypertens. (Greenwich) 2008; 10: 185—194.
  13. Tunon J., Blanco-Colio L. M., Martin-Ventura J. L. Intensive treatment with statins and progression of cardiovascular disease. Nephrol. Dial. Transplant. 2004; 19: 2696—2699.
  14. Tonelly M., Moye L., Sacks F. M. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal failure (CARE). Ann. Intern. Med. 2003; 138: 98—104.
  15. Keech A., Simes R. J., Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet 2005; 366: 1849—1861.
  16. Zhou Y., Kong X., Zhao P. PPAR-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011; 79: 1302—1311.
  17. Gatto A. L., Saag K. G. Management of hyperuricemia and gout in CKD. Am. J. Kidney Dis. 2008; 52: 994—1009.
  18. Contras G., Green T. AASK study group. Blood pressure control and kidney disease. Hypertension 2005; 46: 44—50.
  19. Hair P. I., Scott L. J., Perry C. M.Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67: 95—106.
  20. Mogensen C. E., Viberti G. C. Dual blockade of RAS in patients with hypertension, microalbuminuria and NIDDM: the candesartan and lisinopril microalbuminuria study — CALM. Brit. Med. J. 2000; 321: 1440—1444.
  21. Benson S. C., Pershadsingh H. A., Ho C. I. Identification of telmisartan as a unique AII receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004; 43: 993—1002.
  22. Zhang Z. et al. Combination therapy with AT1 blockers and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin release. Proc. Natl. Acad. Sci. USA 2008; 41: 15896—15901.
  23. Asmus H.-G., Braun J., Krause R. Sevelamer and Ca carbonate effects on cardiovascular calcification and bone density. Nephrol. Dial. Transplant. 2005; 20: 1653—1661.
  24. Olivera R. B., Cancela A. L., Graciolli F. G. Early control of PTH and FGF 23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 2010; 5: 286—291.
  25. Schmieder R.E., Philipp T., Guerediaga J. Long-term antihypertensive efficacy and safety of the direct renin inhibitor aliskiren a 12 month randomized traial with hydrochlorthiazide. Circulation 2009; 119: 417—425.
  26. Rahman M., Pressel S., Davis B. R. Renal outcomes in high-risk hypertensive patients treated with ACEI or calcium channel blocker versus diuretics: a report of ALLHAT trial. Arch. Intern. Med. 2005; 165: 936—946.
  27. Julius S., Kjeldsen S. E., Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimen based on valsartan or amlodipine: the VALUE trial. Lancet 2004; 363: 2022—2031.
  28. Danlof B., Sever P. S. ASCOT investigation: prevention of cardiovascular events with amlodopine adding perindopril. Lancet 2005; 366: 895—906.
  29. Lopez B., Gonzalez A., Hermida N. Myocardial fibrosis in CKD: potential benefits of torasemide. Kidney Int. 2008; 74 (Suppl. 111): S19—S23.
  30. Pitt B., Remme W. J., Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309—1321.
  31. Laville M. Anaemia correction in diabetes trial. New strategies in anaemia management: ACORD. Acta Diabetol. 2004; 41 (Suppl. 1): S18—S22.
  32. Fishbane S. Erythropoiesis-stimulating agent treatment with full anemias correction: a new perspective. Kidney Int. 2009; 75: 358—365.
  33. McGavin J., Keating G. Bisoprolol. A review of its use in chronic heart failure. Drugs 2002; 62: 2677—2696.
  34. Cice G., Ferrara L., Andrea A. Carvedilol increases two-year survival in dialysis patients with cardiomyopathy. J. Am. Coll. Cardiol. 2003; 41: 1438—1444.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies